S
Skvortsova Vi
Researcher at Russian National Research Medical University
Publications - 127
Citations - 5320
Skvortsova Vi is an academic researcher from Russian National Research Medical University. The author has contributed to research in topics: Stroke & Semax. The author has an hindex of 17, co-authored 127 publications receiving 4943 citations. Previous affiliations of Skvortsova Vi include Russian Academy of Sciences.
Papers
More filters
Journal ArticleDOI
Guidelines for management of ischaemic stroke and transient ischaemic attack 2008
Peter A. Ringleb,Marie-Germaine Bousser,Gary A. Ford,Philip M.W. Bath,Michael Brainin,Valeria Caso,Álvaro Cervera,Ángel Chamorro,Charlotte Cordonnier,László Csiba,Antoni Dávalos,Hans-Christoph Diener,José M. Ferro,Werner Hacke,Michael G. Hennerici,Markku Kaste,Peter Langhorne,Kennedy R. Lees,Didier Leys,J. Lodder,Hugh S. Markus,Jean-Louis Mas,Heinrich Mattle,Keith W. Muir,Bo Norrving,Victor Obach,Stefano Paolucci,E. Bernd Ringelstein,Peter D. Schellinger,Juhani Sivenius,Skvortsova Vi,Katharina S. Sunnerhagen,Lars Thomassen,Danilo Toni,Rüdiger von Kummer,Nils Wahlgren,Marion F Walker,Joanna M. Wardlaw +37 more
TL;DR: The article covers referral and emergency management, Stroke Unit service, diagnostics, primary and secondary prevention, general stroke treatment, specific treatment including acute management, management of complications, and rehabilitation.
Journal ArticleDOI
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke
Ralph L. Sacco,Hans-Christoph Diener,Salim Yusuf,Daniel Cotton,Stephanie Ôunpuu,William A. Lawton,Yuko Y. Palesch,Renee H Martin,Gregory W. Albers,Philip M.W. Bath,Natan M. Bornstein,Bernard P.L. Chan,Sien-Tsong Chen,Luís Cunha,Björn Dahlöf,Jacques De Keyser,Geoffrey A. Donnan,Conrado J. Estol,Philip B. Gorelick,Vivian Gu,Karin Hermansson,Lutz Hilbrich,Markku Kaste,Chuanzhen Lu,Thomas Machnig,Prem Pais,Robin S. Roberts,Skvortsova Vi,Philip Teal,Danilo Toni,Cam VanderMaelen,Thor Voigt,Michael A. Weber,Byung-Woo Yoon +33 more
TL;DR: The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel, and there is no evidence that either of the two treatments was superior to the other in the prevention of recurrent strokes.
Journal ArticleDOI
Telmisartan to prevent recurrent stroke and cardiovascular events.
Salim Yusuf,Salim Yusuf,Hans-Christoph Diener,Ralph L. Sacco,Daniel Cotton,Stephanie Ôunpuu,William A. Lawton,Yuko Y. Palesch,Renee H Martin,Gregory W. Albers,Philip M.W. Bath,Natan M. Bornstein,Bernard P.L. Chan,Sien-Tsong Chen,Luís Cunha,Björn Dahlöf,Jacques De Keyser,Geoffrey A. Donnan,Conrado J. Estol,Philip B. Gorelick,Vivian Gu,Karin Hermansson,Lutz Hilbrich,Markku Kaste,Chuanzhen Lu,Thomas Machnig,Prem Pais,Robin S. Roberts,Skvortsova Vi,Philip Teal,Danilo Toni,Cam VanderMaelen,Thor Voigt,Michael A. Weber,Byung-Woo Yoon +34 more
TL;DR: Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes.
Journal ArticleDOI
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study
Hans-Christoph Diener,Ralph L. Sacco,Salim Yusuf,Daniel Cotton,Stephanie Ôunpuu,William A. Lawton,Yuko Y. Palesch,Renee H Martin,Gregory W. Albers,Philip M.W. Bath,Natan M. Bornstein,Bernard P.L. Chan,Sien-Tsong Chen,Luís Cunha,Björn Dahlöf,Jacques De Keyser,Geoffrey A. Donnan,Conrado J. Estol,Philip B. Gorelick,Vivian Gu,Karin Hermansson,Lutz Hilbrich,Markku Kaste,Chuanzhen Lu,Thomas Machnig,Prem Pais,Robin S. Roberts,Skvortsova Vi,Philip Teal,Danilo Toni,Cam VanderMaelen,Thor Voigt,Michael A. Weber,Byung-Woo Yoon +33 more
TL;DR: In this paper, the putative neuroprotective effects of antiplatelet compounds and the angiotensin II receptor antagonist telmisartan were investigated in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial, where patients who had had an ischaemic stroke were randomly assigned in a two by two factorial design to receive either 25 mg aspirin (ASA) and 200 mg extended-release dipyridamole (ER-DP) twice a day or 75 mg clopidogrel once a day, and either 80
Journal Article
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE
Hans-Christoph Diener,Ralph L. Sacco,Salim Yusuf,Daniel Cotton,Stephanie Ôunpuu,William A. Lawton,Yuko Y. Palesch,Renee H Martin,Gregory W. Albers,Philip M.W. Bath,Natan M. Bornstein,Bernard P.L. Chan,Sien-Tsong Chen,Luís Cunha,Björn Dahlöf,Jacques De Keyser,Geoffrey A. Donnan,Conrado J. Estol,Philip B. Gorelick,Vivian Gu,Karin Hermansson,Lutz Hilbrich,Markku Kaste,Chuanzhen Lu,Thomas Machnig,Prem Pais,Robin S. Roberts,Skvortsova Vi,Philip Teal,Danilo Toni,Cam VanderMaelen,Thor Voigt,Michael A. Weber,Byung-Woo Yoon,Christopher F. Bladin +34 more
TL;DR: Disability due to recurrent stroke and cognitive decline in patients with ischaemic stroke were not different between the two antiplatelet regimens and were not affected by the preventive use of telmisartan.